SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Relmada Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
News provided byACCESSWIRE
May 26, 2023, 11:15 PM ET
LOS ANGELES, CA / ACCESSWIRE / May 26, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Relmada Therapeutics, Inc. ("Relmada" or "the Company") (NASDAQ:RLMD) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Relmada announced the results of its RELIANCE III study of drug REL-1017 on October 13, 2022. The Company disclosed that the trial did not reach its primary endpoint, and that "paradoxical results were observed in certain study sites, where [the] placebo dramatically outperformed REL-1017." Based on this news, shares of Relmada dropped by almost 80% on the next day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at email@example.com.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
The Schall Law Firm
Brian Schall, Esq.
SOURCE: The Schall Law Firm
NOTE: This content is not written by or endorsed by "WGNTV", its advertisers, or Nexstar Media Inc.